The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Cancer Research and Treatment. 2023;55(2):479-487 
Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
Value in Health. 2016;19(7):A740-A741
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Biologics: Targets and Therapy. 2012;337
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Cancer Research and Treatment. 2019;51(2):502-509
Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
OncoTargets and Therapy. 2015;1137
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
PharmacoEconomics. 2021;39(5):537-548
FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN
Respirology. 2018;23:293-293
Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)
Lung Cancer. 2012;77:S25
A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Annals of Oncology. 2019;30:ix163
Afatinib/erlotinib/gefitinib
Reactions Weekly. 2018;1705(1):15-15